Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Overview
Date Founded

2011

Headquarters

620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139

Type of Company

Public

Employees (Worldwide)

55

Industries

Biotechnology

Company Description

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Website
Executives & Employees

President, Chief Financial Officer, Chief Executive Officer & Director

Chief Scientific Officer

Chief Medical Officer

Chief Accounting Officer, Vice President-Finance & Controller

Chief Legal Officer

Chief Business Officer

Vice President-Biology

Vice President, Chemistry & Early Development

Founder

Scientific Co-Founder

Subscribe now to see full list of current and former executives
Board of Directors

Executive Chairman at ZappRx, Inc.

Co-Founder at ARCH Venture Partners

Co-Founder at Alnylam Pharmaceuticals, Inc.

Professor of Management Practice at Harvard University - Harvard Business School

President, Chief Financial Officer, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc.

Partner at Polaris Partners

Professional at Samsara Biocapital LLC

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Director at Sarcoma Foundation of America

Founder at Syros Pharmaceuticals, Inc.

Subscribe now to see full list of current and former board members
Paths to Syros Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Syros Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Flagship Pioneering focuses on investments in the following sectors: (1) therapeutics (2) life science tools and diagnostics and (3) bioenergy and clean technology. The firm looks for companies with exceptional management teams and significant commercial opportunities resulting from market discontinuities or technology breakthroughs. Flagship Ventures typically serves as lead investor. The majority of their investments are seed or first round investments. Initial investments range from $250,000 to $5 million, with typically initial investments ranging from $2.5 million to $4 million. Flagship Ventures may invest up to $15 million to $20 million over the life of a venture and typically forms syndicates that include other venture capital firms

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Subscribe now to see full details
Recent Transactions
Details Hidden

Syros Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Syros Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Syros Pharmaceuticals, Inc. issued Common Stock

Subscribe now to see full list of recent transations
Insider Transactions
Details Hidden
Details Hidden
Subscribe now to see full details
Transaction Advisors
Underwriter

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Auditor

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Manager

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Subscribe now to see 6+ more transaction advisors
Legal Advisor

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Associate

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Subscribe now to see 1+ more transaction advisors
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Advisor

Professional at Blueprint Medicines Corp.

Subscribe now to see advisors & consultants for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$313M
Total Enterprise Value
$71M
Earnings Per Share
$-4.05
Revenue
$317K
Net Profit
$-47.7M
EBITDA
$-46.7M
EBITDAMargin
-14.7K%
Total Debt
$221K
Total Equity
$80.6M
Enterprise Value Sales
224.03x
TEVNet Income
-1.49x
Debt TEV
0x
Subscribe now to see full financial details
Investors
Details Hidden

Flagship Pioneering focuses on investments in the following sectors: (1) therapeutics (2) life science tools and diagnostics and (3) bioenergy and clean technology. The firm looks for companies with exceptional management teams and significant commercial opportunities resulting from market discontinuities or technology breakthroughs. Flagship Ventures typically serves as lead investor. The majority of their investments are seed or first round investments. Initial investments range from $250,000 to $5 million, with typically initial investments ranging from $2.5 million to $4 million. Flagship Ventures may invest up to $15 million to $20 million over the life of a venture and typically forms syndicates that include other venture capital firms

Details Hidden

Casdin Capital focuses on investments in disruptive businesses and is positioned to capitalize off an underappreciated, disruptive technology shift currently unfolding in the life sciences and healthcare industry. They consider investment opportunities that span the entire healthcare continuum and into sectors such as agriculture, industrial manufacturing and traditional information technology.

Details Hidden

Aisling invests in life science companies developing biopharmaceutical products and creating businesses based on advanced life science technologies.

Subscribe now to see full details
Suppliers
Dana-Farber Cancer Institute, Inc. Hospitals & Patient Services | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Whitehead Institute for Biomedical Research Commercial Scientific Research | Cambridge, MA

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers. Located in Cambridge, Massachusetts, Whitehead Institute was founded in 1982 by businessman and philanthropist Edwin C. “Jack” Whitehead.

TMRC Co. Ltd. Pharmaceuticals | Tokyo, TY

TMRC Co. Ltd. provides contract research and manufactures medicines. It develops anti-cancer products and those for cancer associated disorders. The company was founded by Hisao Ekimoto in January 2002 and is headquartered in Tokyo, Japan.

Subscribe now to see 1 more suppliers
Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company operates through the following business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. Its baby care franchise includes the JOHNSON'S Baby line of products. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines. The Medical Devices segment includes products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. It include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer, Inc. engages in the manufacture of vaccines and injectable biologic medicines. It operates through the Pfizer Innovative Health and Pfizer Essential Health segments. The Pfizer Innovative Health segment focuses on developing and commercializing novel, value-creating medicines, and vaccines for the internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and consumer healthcare. The Pfizer Essential Health segment comprises of global brands, sterile injectable pharmaceuticals, infusion systems, biosimilars, and Pfizer CentreOne. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Celgene Corp. Pharmaceuticals - Summit, New Jersey

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies